Welcome to our dedicated page for Tenet Healthcare SEC filings (Ticker: THC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Tenet Healthcare’s disclosures can feel like triaging a busy emergency room—hundreds of pages, three operating segments, and intricate Medicare rules pack every document. Whether you need Tenet Healthcare insider trading Form 4 transactions or the cash-flow detail buried in the Tenet Healthcare quarterly earnings report 10-Q filing, raw EDGAR text alone slows decisions.
Stock Titan’s AI quickly converts that overload into plain language. Our engine delivers Tenet Healthcare SEC filings explained simply, highlighting hospital occupancy swings, ambulatory surgery center margins, and Conifer Health Solutions revenue trends. Get push alerts for Tenet Healthcare Form 4 insider transactions real-time, one-click access to management’s risk commentary, and contextual charts that transform numbers into insight.
Use cases investors rely on:
- Compare segment EBITDAR across periods with Tenet Healthcare earnings report filing analysis.
- Answer board questions by understanding Tenet Healthcare SEC documents with AI instead of skimming 300 pages.
- Monitor sentiment via Tenet Healthcare executive stock transactions Form 4 before earnings calls.
The platform covers every form in real time. The Tenet Healthcare annual report 10-K simplified section surfaces payer-mix tables and litigation reserves; the Tenet Healthcare proxy statement executive compensation view breaks down incentive targets; and Tenet Healthcare 8-K material events explained flags sudden divestitures or ASC acquisitions within minutes. From first-read AI summaries to full PDF text, every filing is one search away—so you can focus on diagnosing value, not decoding jargon.
Tenet Healthcare Corp reported an insider equity transaction by CEO and director Saumya Sutaria. On December 31, 2025, 13,016 restricted stock units converted into common stock on a one-for-one basis, increasing his directly held stake.
On the same date, 6,610 shares of common stock were withheld to cover taxes at a price of $198.72 per share. After these transactions, Sutaria directly owned 375,089 shares of Tenet common stock and held 39,049 time-based restricted stock units that continue to vest annually through 2028 under a January 23, 2025 grant.
Tenet Healthcare Corp director Nadja West reported selling 2,178 shares of the company’s common stock on 12/15/2025. The shares were sold at a weighted average price of $197.47 per share in multiple transactions, with prices ranging from $197.47 to $197.57. Following this sale, West beneficially owned 28,480 shares of Tenet Healthcare common stock directly.
THC reports that a holder of its common stock plans to sell 2,178 shares under Rule 144. The sale is expected to be executed through Fidelity Brokerage Services on the NYSE around 12/15/2025, with an aggregate market value of 430,097.46 based on the figures provided.
The shares were acquired on 05/07/2024 through restricted stock vesting from the issuer as compensation. The same table lists 87,885,000 common shares outstanding. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer and, if using a Rule 10b5-1 trading plan, that this representation applied when the plan or trading instructions were adopted.
Tenet Healthcare Corporation reported that Stephen H. Rusckowski has resigned from its board of directors, effective immediately, as of November 21, 2025. Following his departure, the board reduced its size from thirteen to twelve directors. The filing does not describe any changes to management roles or the company’s strategic direction beyond this board adjustment.
Tenet Healthcare Corporation issued new senior notes to refinance existing debt. The company sold $1,500,000,000 of 5.500% senior secured first lien notes due 2032 and $750,000,000 of 6.000% senior notes due 2033. Tenet plans to use the net proceeds, together with cash on hand, to redeem all $1.5 billion of its 6.250% senior secured second lien notes due February 2027 and to partially redeem $0.75 billion of its 6.125% senior notes due October 2028.
The new indentures include covenants that limit certain activities like incurring liens, entering sale and lease-back transactions, and major asset sales, but they allow Tenet and its subsidiaries to incur additional indebtedness and make dividends or other distributions. The notes may be redeemed by Tenet before or after November 15, 2028 at specified prices, including make-whole premiums if redeemed early.
Tenet Healthcare (THC): Insider stock sale disclosed. Principal Accounting Officer R. Scott Ramsey reported open-market sales of common stock on 11/06/2025. Transactions included 8,056 shares at a weighted average price of $204.75 (sold across $204.21–$205.13) and 5,066 shares at a weighted average price of $205.62 (sold across $205.21–$206.14), plus 200 shares at $206.51. After these sales, the table shows beneficial ownership of common stock at 0 shares. The filing lists transaction code “S” for sales and notes weighted-average pricing with details available upon request.
Tenet Healthcare (THC) director Tammy Romo reported an open market sale of company stock. On 11/05/2025, she sold 645 shares of common stock at $205.20 per share, according to a Form 4 insider filing. After this transaction, she directly owns 34,866 shares of Tenet Healthcare common stock.
Tenet Healthcare (THC) filed a Form 144 indicating an intended sale of 13,322 shares of common stock through Fidelity Brokerage Services LLC on or about 11/06/2025, to be sold on the NYSE. The filing lists an aggregate market value of $2,732,412.25 for the proposed sale.
The shares reflect restricted stock that vested on multiple dates and were received as compensation from the issuer. Shares outstanding were 87,885,000; this is a baseline figure, not the amount being sold.
Tenet Healthcare (THC) director Tammy Romo reported open‑market sales of 26,855 shares on November 3–4, 2025. Trades occurred in multiple transactions within a per‑share range of $200.00 to $204.93, with weighted‑average prices disclosed for each tranche.
Following these transactions, Romo beneficially owns 35,511 shares, held directly. The filing lists tranches of 8,654, 5,945, 500, 11,410 and 346 shares at weighted‑average prices of $200.43, $201.23, $202.27, $204.04 and $204.93, respectively.
Tenet Healthcare Corporation entered a new senior secured asset‑based revolving credit facility of up to $1.9 billion, including a $200 million sub‑facility for letters of credit. Borrowing availability is tied to a borrowing base of eligible accounts receivable, inventory and Medicaid supplemental payments. The facility is guaranteed by certain domestic wholly owned hospital subsidiaries and secured by a first‑priority lien on accounts receivable and inventory.
Loans bear interest at a base rate plus 0.25%–0.50% or SOFR/EURIBOR plus 1.25%–1.50%, with a 0.25% commitment fee on undrawn commitments. It terminates on November 4, 2030 or earlier upon specified springing maturities tied to certain senior notes, subject to stated conditions. Tenet also amended and extended its separate $200 million letter of credit facility to November 4, 2030, with an unused fee of 0.25% and a 1.25% fee on issued but undrawn letters; unreimbursed drawings accrue at base rate plus 0.25%.
FAQ
What is the current stock price of Tenet Healthcare (THC)?
What is the market cap of Tenet Healthcare (THC)?
